Previous studies have demonstrated that treatment with PCSK9 inhibitors lowered plasma LDL-C levels by about 50% and led to an increase in hepatic LDL receptor function, resulting in the reversal of lipid accumulation in patients with FH [27]. Here, PCSK9 is linked to familial hyperaldosteronism.